Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Blood|August 29, 2012
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemiaAllen B Williams, Li Li, Bao Nguyen, et al.
Blood|December 17, 2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLKeith W Pratz, Takashi Sato, Kathleen M Murphy, et al.
Blood|November 15, 2013
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsAllison Galanis, Hayley Ma, Trivikram Rajkhowa, et al.
Blood|November 1, 2003
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expressionRui Zheng, Alan D Friedman, Mark Levis, et al.
Oncology and Therapy|July 7, 2017
Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature ReviewEllen E Korol, Sisi Wang, Karissa Johnston, et al.
Blood|May 21, 2013
FLT3 inhibitor-induced neutrophilic dermatosisAmir T Fathi, Long Le, Robert P Hasserjian, et al.
Blood|October 23, 2004
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survivalKyu-Tae Kim, Kristin Baird, Joon-Young Ahn, et al.
Leukemia Research|November 21, 2020
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypesBreann Yanagisawa, Brandy Perkins, Theodoros Karantanos, et al.
Blood|May 29, 2004
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibitionPatrick Brown, Soheil Meshinchi, Mark Levis, et al.
Oncotarget|January 13, 2017
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitorsBao Nguyen, Allen B Williams, David J Young, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Blood|August 29, 2012
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemiaAllen B Williams, Li Li, Bao Nguyen, et al.
Blood|December 17, 2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLKeith W Pratz, Takashi Sato, Kathleen M Murphy, et al.
Blood|November 15, 2013
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsAllison Galanis, Hayley Ma, Trivikram Rajkhowa, et al.
Blood|November 1, 2003
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expressionRui Zheng, Alan D Friedman, Mark Levis, et al.
Oncology and Therapy|July 7, 2017
Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature ReviewEllen E Korol, Sisi Wang, Karissa Johnston, et al.
Blood|May 21, 2013
FLT3 inhibitor-induced neutrophilic dermatosisAmir T Fathi, Long Le, Robert P Hasserjian, et al.
Blood|October 23, 2004
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survivalKyu-Tae Kim, Kristin Baird, Joon-Young Ahn, et al.
Leukemia Research|November 21, 2020
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypesBreann Yanagisawa, Brandy Perkins, Theodoros Karantanos, et al.
Blood|May 29, 2004
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibitionPatrick Brown, Soheil Meshinchi, Mark Levis, et al.
Oncotarget|January 13, 2017
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitorsBao Nguyen, Allen B Williams, David J Young, et al.
Pageof 10